课题基金 / 基金详情

Design of the nanointerface for detection, recovery, and regeneration of abnormal proteins

Design of the nanointerface for detection, recovery, and regeneration of abnormal proteins
用于异常蛋白质检测、回收和再生的纳米界面设计
批准号:
14380412
负责人:
FUJIMOTO Keiji
金额:
$7.1万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

FUJIMOTO Keiji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Polymeric nanoparicles have been paid to attention as a drug carrier. It is required that carriers are inert and non-toxic and are not accumulated or are degradable in the body. Therefore we selected poly-L-lysine (PLL) that is degradable polypeptide for a backbone of a nanoparticle. Because PLL exhibits structural changes among random, helix, and β-sheet by pH and temperature, we expect the stimuli-sensitive release of drugs from nanoparticles.PLL was allowed to react with poly (ethylene glycol) (PEG) to improve the dispersion-stability and to prolong the lifetime in blood (mPEG-PLL polymer). Then, mPEG-PLL polymer was coupled with phosphatidic acid (PA) that acts as a hydrophobic site (mPEG-PLL-PA nanoparticle). The obtained polymers spontaneously aggregated into a nanoparticulate shape by the hydrophobic association among PA moieties. Whilst mPEG-PLL polymers were assembled to nanoparticles upon the formation of β-sheet structure in high pHs and high temperatures (mPEG-PLL nanoparticle). Both nanoparticles were 10-80nm in size and possessed the positive change. FITC-labeled nanoparticles were internalized into A431 cells. Adriamycin (ADR) that is an anticancer drug was incorporated into mPEG-PLL-PA nanoparticle more than mPEG-PLL nanoparticle because of PA's great hydrophobicity. However, drug release showed an opposite tendency. In pH4, release rate of ADR from mPEG-PLL nanoparticles was faster than that from mPEG-PLL-PA nanoparticles. Thereby survival rate of A431 cells decreased when they were treated with ADR-loaded mPEG-PLL nanoparticles.We applied β-sheet association of the mPEG-PLL polymer to inhibition of protein aggregation. PLL tends to aggregate through β-sheet association by raising pH and temperature. This aggregation could be inhibited by adding the mPEG-PLL polymer. This suggests that the mPEG-PLL polymer is capable of inhibiting aggregation of abnormal proteins that cause conformational diseases.
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
異方性粒子の作製とそのはたらき
各向异性颗粒的制备及其功能
DOI: --
发表时间: 2005
期刊: 繊維と工業 61・1
影响因子: --
作者: [藤本啓二]
通讯作者: 藤本啓二
藤本啓二: "ナノ粒子"血液・免疫・腫瘍. Vol.8. 119-123 (2003)
Keiji Fujimoto:“纳米颗粒”血液、免疫学和肿瘤,第 8 卷(2003 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
リボソームを鋳型とする中空ナノ粒子の作製方法
以核糖体为模板制备中空纳米粒子的方法
DOI: --
发表时间: 2004
期刊:
影响因子: --
作者: []
通讯作者:
11
    Soluble urokinase receptor; a new diagnostic and therapeutic biomarker for nephrotic syndrome
    • 批准号:
      18K15988
    • 项目类别:
      Grant-in-Aid for Early-Career Scientists
    • 资助金额:
      $2.58万
    • 财政年份:
      2018
    • 负责人:
      FUJIMOTO Keiji
    • 依托单位:
    Development of next generation nano-biomaterials by cell surface engineering
    • 批准号:
      19300176
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.06万
    • 财政年份:
      2007
    • 负责人:
      FUJIMOTO Keiji
    • 依托单位:
    海外基金